New Swedish company, Galecto Biotech, launched

Tuesday 3 January 2012

A new Swedish company, Galecto Biotech AB, has received venture funding to develop small-molecule modulators of the galectin family of proteins that could potentially treat fibrosis, inflammation and other diseases.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Sweden